304 related articles for article (PubMed ID: 16188168)
1. Rational drug design and PPAR agonists.
Perfetti R; D'Amico E
Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
3. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones in the treatment of type 2 diabetes.
Pittas AG; Greenberg AS
Expert Opin Pharmacother; 2002 May; 3(5):529-40. PubMed ID: 11996632
[TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
Vasudevan AR; Balasubramanyam A
Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
8. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
9. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
11. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
12. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
13. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
[TBL] [Abstract][Full Text] [Related]
15. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
Karak M; Bal NC; Bal C; Sharon A
Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
17. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
18. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
20. The next generation of PPAR drugs: do we have the tools to find them?
Shearer BG; Billin AN
Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]